Is Levophed (norepinephrine) given in pulseless electrical activity (PEA)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 28, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Levophed (Norepinephrine) in Pulseless Electrical Activity (PEA)

Levophed (norepinephrine) is not recommended for routine use in pulseless electrical activity (PEA) cardiac arrest. The American Heart Association guidelines specifically recommend epinephrine as the primary vasopressor for PEA, with no recommendation for norepinephrine in this setting 1, 2.

Standard Management of PEA

  • High-quality CPR with minimal interruptions in chest compressions is the foundation of PEA management 2
  • Epinephrine 1 mg IV/IO should be administered every 3-5 minutes during cardiac arrest resuscitation 3, 2
  • Identification and treatment of potentially reversible causes is crucial for improving outcomes in PEA 2
  • Atropine and transcutaneous pacing should be considered if asystole and/or PEA are present, particularly in anaphylaxis-related cardiac arrest 1

Vasopressors in Cardiac Arrest

  • Epinephrine is the primary vasopressor recommended for all forms of cardiac arrest including PEA 1, 3
  • While vasopressors may improve return of spontaneous circulation (ROSC) and short-term survival, there is insufficient evidence that they improve survival to discharge or neurological outcomes 1
  • For PEA specifically, the American Heart Association recommends epinephrine 0.01 mg/kg every 3-5 minutes while CPR continues 2
  • There is no specific recommendation for norepinephrine (Levophed) use in the PEA cardiac arrest algorithm 1

Special Considerations

  • For hypotension that is refractory to volume replacement and epinephrine injections (not in cardiac arrest), dopamine can be considered as a vasopressor infusion 1
  • In anaphylaxis-related cardiac arrest with PEA, high-dose epinephrine administration is recommended, with potential consideration of higher subsequent dosages (0.1-0.2 mg/kg) for unresponsive PEA 1
  • Prolonged resuscitation efforts are encouraged in PEA, as they are more likely to be successful, particularly when the patient is young with a healthy cardiovascular system 1, 4

Underlying Causes of PEA

  • PEA is often caused by reversible conditions that should be identified and treated promptly 2, 5
  • The "H's and T's" should be considered: Hypovolemia, Hypoxia, Hydrogen ion (acidosis), Hypo/hyperkalemia, Hypothermia, Toxins, Tamponade (cardiac), Tension pneumothorax, Thrombosis (coronary or pulmonary) 2
  • For suspected pulmonary embolism causing PEA, thrombolysis may be considered, with studies showing improved outcomes with early administration 2, 6

Common Pitfalls

  • Failing to identify and treat the underlying cause of PEA, which is essential for successful resuscitation 2, 5
  • Not recognizing that different presentations of PEA (primary vs. secondary after other rhythms) may have different probabilities of achieving ROSC 4
  • Using high-dose epinephrine routinely without specific indications 3
  • Premature termination of resuscitation efforts in PEA, when continued efforts may be beneficial 1, 4

In summary, while vasopressors are used in cardiac arrest management, current guidelines specifically recommend epinephrine for PEA, with no recommendation for routine use of norepinephrine (Levophed) in this setting.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Pulseless Electrical Activity (PEA) and Patient Survival

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Maximum Epinephrine Dosage in Cardiac Arrest

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.